Galectin-3 serum levels are independently associated with microalbuminuria in chronic heart failure outpatients
Massimo Iacoviello1, Nadia Aspromonte2, Marta Leone3, Valeria Paradies3, Valeria Antoncecchi3, Roberto Valle4, Pasquale Caldarola5, Marco Matteo Ciccone3, Loreto Gesualdo6, Francesca Di Serio7
1 Department of Cardiothoracic, Cardiology Unit, Policlinic University Hospital, Bari, Italy
2 DEA Department, Cardiology Unit, San Filippo Neri Hospital, Rome, Italy
3 Department of Emergency and Organ Transplantation, School of Cardiology, University of Bari, Bari, Italy
4 Cardiology Unit, Hospital Department, Chioggia ULSS 14, Chioggia, Italy
5 Cardiology Unit, Cardiology Department, San Paolo Hospital, Bari, Italy
6 Department of Diagnostic Pathology, Bioimages and Public Health, Policlinic University Hospital, Bari, Italy
7 Clinical Pathology Unit, University of Bari, Bari, Italy
Department of Cardiothoracic, Cardiology Unit, Policlinic University Hospital, Bari
Source of Support: None, Conflict of Interest: None
Background: Galectin-3 (Gal-3) is a novel biomarker reflecting inflammation status and fibrosis involving worsening of both cardiac and renal functions.
Objectives: The aim of this study was to evaluate the relationship between Gal-3 serum levels and microalbuminuria in a group of chronic heart failure (CHF) outpatients.
Patients and Methods: We enrolled CHF outpatients having stable clinical conditions and receiving conventional therapy. All patients underwent clinical evaluation, routine chemistry analysis, echocardiography, and evaluation of the urinary albumin/creatinine ratio (UACR).
Results: Among the patients enrolled, 61 had microalbuminuria (UACR, 30-299) and 133 normoalbuminuria (UACR, < 30). Patients with normoalbuminuria showed significantly higher levels of Gal-3 than those without (19.9 ± 8.8 vs. 14.6 ± 5.5 ng/mL). The stepwise regression analysis indicated that Gal-3 was the first determinant of microalbuminuria (odds ratio [OR]: 1.08; 95% confidence interval [CI]: 1.02 - 1.14, P = 0.012), followed by diabetes (OR 2.14; 95% CI: 1.00 - 4.57; P = 0.049) and high central venous pressure (OR 2.80; 95% CI: 1.04 - 7.58; P= 0.042).
Conclusions: Our findings indicate an independent association between Gal-3 levels and microalbuminuria, an early marker of altered renal function. This suggests the possible role of Gal-3 in the progression of cardiorenal syndrome in CHF outpatients.